Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07135973 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)

Name: A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD) — clinical trial record (NCT07135973)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 4

SponsorSanofi

Started2026-08-10

View on ClinicalTrials.gov ↗

This is an interventional phase IV clinical study which is single-arm study for assessing the safety of belumosudil in Indian patients who are12 years and older. Study details include: * The study duration will be up to 12 months per participant. * The treatment duration will be up to 24 weeks. * The number of visits will be 7.

Amendment record

Amended 3 times since 2025-08-14; most recent filed 2026-05-11. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-31.

2026-05-11

Amendment Study Status v3

2026-02-27

Amendment Study Status, Eligibility v2

2025-10-29

Amendment Study Status, Contacts/Locations v1

2025-08-14

Original filing

Trial Details

NCT Number	NCT07135973
Lead Sponsor	Sanofi
Conditions	Chronic Graft Versus Host Disease
Enrollment	26 participants
Start Date	2026-08-10
Primary Completion	2027-08-30 (estimated)
Study Completion	2028-03-17 (estimated)
Updated on ClinicalTrials.gov	2026-05-12